Skip to main content
Signal8

Zenas BioPharma, Inc. (ZBIO)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc.

NASDAQ:ZBIOHealthcare
Pre+0.00%$28.26
Close$28.26+8.99%AH$28.26+0.00%vs close
Mkt Cap$1.92B
Float31.16M
O/S67.82M
Inst Own91.6%
SI40.2%
Dilution
Zenas BioPharma, Inc. logoNASDAQ:ZBIOPre$28.26+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202626.2128.4425.8328.26543,969
Nov 5, 202628.1028.4925.7925.93825,642
Nov 4, 202629.2729.9128.0128.46800,741
Nov 3, 202627.8529.0527.8428.38572,844
Nov 2, 202628.4729.0927.1427.62408,284
Oct 30, 202628.3529.1127.9128.39358,070
Oct 29, 202629.0829.6128.3728.76373,026
Oct 28, 202627.1029.0727.0328.77394,278
Oct 27, 202627.0928.2326.7227.30581,012
Oct 26, 202627.1828.1826.6827.24371,648
Oct 23, 202628.0028.3326.7326.87377,550
Oct 22, 202627.9528.8327.5128.23406,015
Oct 21, 202628.4729.4427.8928.08483,990
Oct 20, 202626.3829.7026.3828.18549,018
Oct 19, 202625.0827.5525.0826.71696,545
Oct 16, 202625.3625.9624.5124.84661,797
Oct 15, 202624.9625.9424.2525.40471,939
Oct 14, 202624.8226.4924.3924.86425,053
Oct 13, 202626.1127.0025.0425.16519,662
Oct 12, 202626.9327.4926.3026.40602,493
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$32.00+13.2%
Low $32High $32
Ratings Distribution
BUY
4
HOLD
1
SELL
0
TOTAL5
Insider Trades
InsiderTypeShares
Oliger Christy J. profile photoOliger Christy J.Grant/Award37.0K
Lu Hongbo profile photoLu HongboGrant/Award18.5K
ORLOFF JOHN J profile photoORLOFF JOHN JGrant/Award18.5K
MOULDER LEON O JR profile photoMOULDER LEON O JRGrant/Award500.0K
Nunn Jason Raleigh profile photoNunn Jason RaleighGrant/Award18.5K
Fox Jennifer A. profile photoFox Jennifer A.Grant/Award125.0K
Shareholders
91.6%
Institutional
(150)
1.2%
Insiderⓘ
(6)
30.7%
5%+ Owners
(7)
-
Unattributed (incl. retail)ⓘ
Institutional91.6%
Insider1.2%
5%+ Beneficial30.7%
Sources: 13F, Form 4, 13D/13GO/S: 67.8M · as of 30 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments.

The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.

Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023.

Its headquarters are located in Waltham, Massachusetts.

Key Metrics
Market Cap$1.92B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership91.63%

based on 67.82M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateSep 12, 2024
Shares Outstanding67.82M
Authorized Shares
Float31.16M
52-Week Range
$13.50$44.60
$28.26(47th percentile)
Volume
Average Daily Volume521.18K
543.97K today vs 521.18K avg(+4%)

30d Avg

521.18K

60d Avg

637.79K

90d Avg

660.98K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...